Abstract
In preclinical studies, neural stem cell (NSC)-based delivery of oncolytic virus has shown great promise in the treatment of malignant glioma. Ensuring the success of this therapy will require critical evaluation of the spatial distribution of virus after NSC transplantation. In this study, the patient-derived GBM43 human glioma line was established in the brain of athymic nude mice, followed by the administration of NSCs loaded with conditionally replicating oncolytic adenovirus (NSC-CRAd-S-pk7). We determined the tumor coverage potential of oncolytic adenovirus by examining NSC distribution using magnetic resonance (MR) imaging and by three-dimensional reconstruction from ex vivo tissue specimens. We demonstrate that unmodified NSCs and NSC-CRAd-S-pk7 exhibit a similar distribution pattern with most prominent localization occurring at the tumor margins. We were further able to visualize the accumulation of these cells at tumor sites via T2-weighted MR imaging as well as the spread of viral particles using immunofluorescence. Our analyses reveal that a single administration of oncolytic virus-loaded NSCs allows for up to 31% coverage of intracranial tumors. Such results provide valuable insights into the therapeutic potential of this novel viral delivery platform.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.
Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P . Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Sem Oncol 2011; 38: 243–253.
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846–12851.
Benedetti S, Pirola B, Magrassi L, Bruzzone MG, Rigamonti D et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nature Med 2000; 6: 447–450.
Gutova M, Shackleford GM, Khankaldyyan V, Herrmann KA, Shi XH, Mittelholtz K et al. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Ther 2013; 20: 143–150.
Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cell Transl Med 2013; 2: 983–992.
Seol HJ, Jin J, Seong DH, Joo KM, Kang W, Yang H et al. Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett 2011; 311: 152–159.
Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS ONE 2009; 4: e8314.
Ehtesham M, Kabos P, Gutierrez MAR, Chung NHC, Griffith TS, Black KL et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62: 7170–7174.
Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 2011; 19: 1714–1726.
Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 2013; 105: 968–977.
Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009; 16: 262–278.
Thaci B, Ahmed AU, Ulasov IV, Tobias AL, Han Y, Aboody KS et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 2012; 19: 431–442.
Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm 2011; 8: 1559–1572.
Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J . Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol 2012; 797: 111–125.
Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012; 104: 42–55.
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18: 589–602.
Lin D, Najbauer J, Salvaterra PM, Mamelak AN, Barish ME, Garcia E et al. Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma. Neuroimage 2007; 37 (Suppl 1): S18–S26.
Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncol 2005; 7: 164–176.
Aboody KS, Najbauer J, Metz MZ, D’Apuzzo M, Gutova M, Annala AJ et al. Neural stem cell–mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 2013; 5: 184ra59.
Gutova M, Frank JA, D'Apuzzo M, Khankaldyyan V, Gilchrist MM, Annala AJ et al. Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cell Transl Med 2013; 2: 766–775.
Thu MS, Najbauer J, Kendall SE, Harutyunyan I, Sangalang N, Gutova M et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS ONE 2009; 4: e7218.
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20: 1063–1068.
Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006; 94: 108–114.
Fiala JC . Reconstruct: a free editor for serial section microscopy. J Microsc 2005; 218: 52–61.
Bensaïd W, Triffitt JT, Blanchat C, Oudina K, Sedel L, Petite H . A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. Biomaterials 2003; 24: 2497–2502.
Tate CC, Shear DA, Tate MC, Archer DR, Stein DG, LaPlaca MC . Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. J Tissue Eng Regen M 2009; 3: 208–217.
Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cell 2008; 26: 1406–1413.
An JH, Lee SY, Jeon JY, Cho KG, Kim SU, Lee MA . Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 2009; 8: 2873–2881.
Acknowledgements
We thank Ms. Lingjiao Zhang for her expertise in the statistical analysis of our studies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AJA and KSA are share-holders, directors and officers of TheraBiologics, a clinical stage biopharmaceutical company focused on the development of stem cell-mediated cancer therapy. RAM is a director of TheraBiologics.
Additional information
Supplementary Information accompanies the paper on Cancer Gene Therapy website
Rights and permissions
About this article
Cite this article
Morshed, R., Gutova, M., Juliano, J. et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther 22, 55–61 (2015). https://doi.org/10.1038/cgt.2014.72
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2014.72
This article is cited by
-
Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients
Cancer Gene Therapy (2021)
-
Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas
Cell Death & Disease (2020)
-
Gene Delivery in Neuro-Oncology
Current Oncology Reports (2017)
-
Evaluation of tongue squamous cell carcinoma resection margins using ex-vivo MR
International Journal of Computer Assisted Radiology and Surgery (2017)